MARKET

XENT

XENT

Intersect ENT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.32
+0.46
+2.58%
After Hours: 18.32 0 0.00% 16:00 09/13 EDT
OPEN
17.86
PREV CLOSE
17.86
HIGH
18.45
LOW
17.70
VOLUME
474.97K
TURNOVER
--
52 WEEK HIGH
35.87
52 WEEK LOW
15.01
MARKET CAP
576.58M
P/E (TTM)
-16.2714
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XENT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XENT News

  • Intersect ENT (XENT) Down 18.6% Since Last Earnings Report: Can It Rebound?
  • Zacks.08/31 13:32
  • Stocks That Hit 52-Week Lows On Thursday
  • Benzinga.08/22 15:12
  • Edited Transcript of XENT earnings conference call or presentation 1-Aug-19 8:30pm GMT
  • Thomson Reuters StreetEvents.08/09 18:55
  • Intersect (XENT) Q2 Loss Wider Than Estimates, Revenues Miss
  • Zacks.08/05 13:08

More

Industry

Medical Equipment, Supplies & Distribution
-0.59%
Healthcare Equipment & Supplies
-0.35%

Hot Stocks

Name
Price
%Change

About XENT

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
More

Webull offers Intersect ENT Inc (XENT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.